Vitolo U et al. -Rituximab-cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) is the standard of care in previously untreated diffuse large B-cell lymphoma (DLBCL). In the current randomized phase III study, obinutuzumab (G)-CHOP with R-CHOP in such patients. It was shown that G-CHOP did not improve progression-free survival compared with R-CHOP in patients with previously untreated DLBCL.